对肥胖相关脏病的分子洞察:临床影响及其管理的可能策略
1Department of Pharmacology, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi, 110062, India.
Current drug targets
|October 16, 2024
概括
肥胖显著增加慢性病 (CKD) 的风险. 了解与肥胖相关的病机制有助于制定有效的管理策略,以保护脏健康.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 肥胖是一个全球健康危机,与许多疾病有关,包括慢性病 (CKD).
- 肥胖相关脏病 (OAN) 是一个日益关注的问题,对CKD的患病率和严重程度作出了重大贡献.
- 了解OAN的分子通路对于有效的临床管理至关重要.
研究的目的:
- 研究驱动肥胖相关脏病 (OAN) 的分子机制.
- 探索OAN的临床影响和表现.
- 审查OAN目前和新兴的管理策略.
主要方法:
- 对OAN中涉及胰岛素抵抗,炎症和激素系统的分子机制的审查.
- 对蛋白尿,膜过率 (GFR) 和进展为CKD的临床数据的分析.
- 治疗干预措施的评估,包括生活方式的改变和药理学药剂.
主要成果:
- OAN的发病包括胰岛素抵抗,高胰岛素血症,炎症和RAAS激活,导致球膜过和高血压.
- OAN的临床症状包括蛋白尿和降低的GFR,往往进展为CKD.
- 减肥,GLP-1受体激动剂,SGLT2抑制剂和RAAS抑制剂在管理OAN方面表现有前途.
结论:
- 肥胖相关脏病是一种由代谢和荷尔蒙失调驱动的复杂疾病.
- 早期检测和多方面的管理,包括生活方式和向药物治疗,对于保持功能至关重要.
- 对OAN机制的进一步研究可以导致改进的脏保护策略.
更多相关视频
10:37Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
100
14:56Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies
Published on: May 6, 2022
4.4K
相关概念视频
01:24Obesity
388
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
388
01:26Nephrotic Syndrome II : Assessment and Medical Management
2
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
2
01:24Nephrotic Syndrome III : Nursing Management
2
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
2
01:24Nephrotic Syndrome I : Introduction
2
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
2
01:28Chronic Kidney Disease III: Interprofessional Care
2
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
2
01:15Diabetes: Management and Pharmacotherapy
238
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
238